Showing 6711-6720 of 18626 results for "".
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
https://reachmd.com/clinical-practice/cardiology/victor-trial-results-vericiguat-efficacy-and-safety-across-baseline-background-therapy-in-contemporary-ambulatory-patients-with-hfref/39253/VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEFGDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
https://reachmd.com/programs/cme/unlocking-the-csf1r-code-targeted-pathways-and-tailored-choices/48905/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.The Role of Occupational Therapy in Schizophrenia Management
https://reachmd.com/programs/neurofrontiers/the-role-of-occupational-therapy-in-schizophrenia-management/17872/Occupational therapists play an integral role in the treatment plan for our patients with schizophrenia. Find out more.Minimal Hepatic Encephalopathy: A Covert Operation?
https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-A-Covert-Operation/39788/Explore diagnostic and treatment challenges in patients with hepatic encephalopathy to improve outcomes for your patients.VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
https://reachmd.com/clinical-practice/cardiology/victor-prespecified-analysis-results-vericiguat-effects-on-mortality-in-ambulatory-patients-with-hfref/39252/VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEFBest Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection
https://reachmd.com/programs/cme/Best-Practices-for-Optimized-Photobiomodulation-Treatment-Effect-Candidate-Selection/35949/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effClinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
https://reachmd.com/programs/cme/clinical-conundrums-in-aria-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/Enhance your multidisciplinary approach to ARIA management in Alzheimer's patients with The ARIA Toolkit. Tackle the challenges of ARIA management with concise 5-minute episodes featuring real-world scenarios, practical tips, and expert insights across clinical specialties.Stopping Stigma Surrounding Monkeypox with Provider Education
https://reachmd.com/programs/neurofrontiers/stopping-stigma-surrounding-monkeypox-with-provider-education/15387/Here’s how educational talks can improve mental healthcare providers’ knowledge and comfort surrounding the recent monkeypox outbreak.The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.